These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 9884251)

  • 1. Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral.
    Otto MG; Mayer AD; Clavien PA; Cavallari A; Gunawardena KA; Mueller EA
    Transplantation; 1998 Dec; 66(12):1632-40. PubMed ID: 9884251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group.
    Keown P; Niese D
    Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group.
    Frei UA; Neumayer HH; Buchholz B; Niese D; Mueller EA
    Transplantation; 1998 Jun; 65(11):1455-60. PubMed ID: 9645802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The U.K. Neoral Renal Study Group.
    Pollard SG; Lear PA; Ready AR; Moore RH; Johnson RW
    Transplantation; 1999 Nov; 68(9):1325-31. PubMed ID: 10573071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microemulsion formulation of cyclosporin (Sandimmun Neoral) vs Sandimmun: comparative safety, tolerability and efficacy in severe active rheumatoid arthritis. On behalf of the OLR 302 Study Group.
    Yocum DE; Allard S; Cohen SB; Emery P; Flipo RM; Goobar J; Jayawardena S; Job-Deslandre C; Jubb RW; Krüger K; Lopes Vaz A; Manger B; Mur E; Nygaard H; Weiner SM; Rainer F; Sack MR; Schiff MH; Schnitzer TJ; Trigg LB; Whatmough I; Schmidt AG
    Rheumatology (Oxford); 2000 Feb; 39(2):156-64. PubMed ID: 10725065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients.
    Taesch S; Niese D
    Transpl Int; 1994; 7 Suppl 1():S263-6. PubMed ID: 11271220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
    Canadian Neoral Renal Transplantation Study Group
    Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of diltiazem on concentration of cyclosporin metabolites in Sandimmune and Neoral treated kidney transplant patients].
    Sperschneider H; Wagner C; Korn A; Christians U
    Med Klin (Munich); 1997 Oct; 92(10):589-96. PubMed ID: 9446006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoral compared to Sandimmune is associated with a decrease in histologic severity of rejection in patients undergoing primary liver transplantation.
    Graziadei IW; Wiesner RH; Marotta PJ; Porayko MK; Dahlke LJ; Wilson SM; Steers JL; Krom RA
    Transplantation; 1997 Sep; 64(5):726-31. PubMed ID: 9311710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
    Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L
    Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NOF-11: a one-year pediatric randomized double-blind comparison of neoral versus sandimmune in orthotopic liver transplantation.
    Alvarez F; Atkison PR; Grant DR; Guilbault N; Jones AB; Kim PS; Kneteman NM; Laurin L; Martin SR; Murphy GF; Paradis K; Shapiro J; Smith LJ; Superina RA
    Transplantation; 2000 Jan; 69(1):87-92. PubMed ID: 10653385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using cyclosporine Neoral immediately after liver transplantation. United Kingdom Neoral Pilot Study Group.
    Tredger JM
    Ther Drug Monit; 1995 Dec; 17(6):638-41. PubMed ID: 8588234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine--results at six months after transplantation.
    Eisen HJ; Hobbs RE; Davis SF; Laufer G; Mancini DM; Renlund DG; Valantine H; Ventura H; Vachiery JL; Bourge RC; Canver CC; Carrier M; Costanzo MR; Copeland J; Dureau G; Frazier OH; Dorent R; Hauptman PJ; Kells C; Master R; Michaud JL; Paradis I; Smith A; Vanhaecke J; Mueller EA
    Transplantation; 1999 Sep; 68(5):663-71. PubMed ID: 10507486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability.
    Zachariae H; Abrams B; Bleehen SS; Bräutigam M; Burrows D; Ettelt MJ; Fry L; Happle R; Haustein UF; Ganslandt J; Jung EG; Knop J; Kühne KH; Mellein B; Mørk NJ; Rogers S; Schmidt AG; Schopf RE; Sumner M; Taube KM; Weidinger G; Wurdel C; Zahn E
    Dermatology; 1998; 196(2):231-6. PubMed ID: 9568413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period.
    Wahlberg J; Wilczek HE; Fauchald P; Nordal KP; Heaf JG; Olgaard K; Hansen JM; Lokkegaard H; Mueller EA; Kovarik JM
    Transplantation; 1995 Oct; 60(7):648-52. PubMed ID: 7570970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Passage from sandimmun to neoral in kidney transplantation in children].
    Broyer M; Maisin A; Guest G; Baudouin V; Charbit M; Reigneau O; Loirat C
    Arch Pediatr; 1999 Oct; 6(10):1066-9. PubMed ID: 10544781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of cyclosporine in pediatric long-term liver transplant recipients converted from Sandimmun to Neoral.
    Melter M; Rodeck B; Kardorff R; Hoyer PF; Brodehl J
    Transpl Int; 1997; 10(6):419-25. PubMed ID: 9428114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8).
    Grant D; Kneteman N; Tchervenkov J; Roy A; Murphy G; Tan A; Hendricks L; Guilbault N; Levy G
    Transplantation; 1999 Apr; 67(8):1133-7. PubMed ID: 10232563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label study of the safety and tolerability of converting stable liver transplant recipients to neoral.
    Pasha TM; Wiesner RH; Dahlke LM; Porayko MK; Krom RA
    Liver Transpl Surg; 1998 Sep; 4(5):410-5. PubMed ID: 9724479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporin microemulsion (Neoral). A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation.
    Coukell AJ; Plosker GL
    Pharmacoeconomics; 1998 Dec; 14(6):691-708. PubMed ID: 10346420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.